SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Trumps statement that the U.S. would not strike Iran has fueled hopes of a relief bounce in SPY, though traders remain divided over whether the pause signals de-escalation or merely delays further conflict. Persistent worries about oil-driven inflation and possible renewed hostilities, alongside the Fed decision and major tech earnings, are keeping volatility and downside risks in focus.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus recurrent glioblastoma REGAIN trial and upcoming clinical data are the dominant focus, with traders citing the early results as encouraging while acknowledging the evidence comes from a small patient group. The Samsung Medical Center MOU for exploring a pancreatic cancer study is also drawing attention as a secondary pipeline development.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas futures trading, with traders debating weather forecasts, storage injections, production and pipeline disruptions as drivers of sharp swings. Bears point to mild-weather expectations, ample supply and the ETFs leverage and futures-roll decay, while bulls are watching for winter demand or tighter storage to support a rebound.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is drawing attention as traders position for weaker natural-gas prices, citing ample storage, strong production, and expectations for mild weather to restrain demand. Others warn that heat, tighter storage reports, or LNG disruptions could trigger sharp counter-rallies, adding to volatility in the leveraged inverse fund.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyvernas positive registrational-trial results for miv-cel in stiff person syndrome, alongside encouraging longer-term data in generalized myasthenia gravis, are driving attention. Traders are impressed by the durability and breadth of benefit, but the stocks sharp swings have prompted debate over serious adverse events, profit-taking, and possible dilution.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs upcoming quarterly report is the main focus, with traders weighing a lowered bookings outlook and soft spending against resilient user engagement and interest in viral games. Some see reset expectations as a chance for a better reaction, while others worry the company could again fall short of the markets bar after prior post-earnings selloffs.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers climb back toward $30 and a new 52-week high is the dominant conversation, with traders celebrating a long-awaited rebound and pointing to pipeline progress and defensive-sector interest. Others question whether the move can hold, citing resistance near $30 and lingering concerns about patent expirations and the need for stronger growth catalysts.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidentals recent strength is drawing attention as traders watch a technical breakout and position ahead of the upcoming earnings report, with firm crude prices and broader energy-sector gains providing context. The mood is largely bullish on momentum, though some traders question whether the shares are keeping pace with oil and note their sensitivity to volatile geopolitical headlines.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazils presidential runoff is driving attention, with traders attributing EWZs rally and heavy call activity to expectations of a Flvio Bolsonaro win, though the result remains uncertain. The bullish positioning is tempered by put buying and concern that the election move may already be priced in, leaving traders focused on event volatility.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a volatile tech-led selloff and rebound, with traders debating whether concerns about AI spending and financing, alongside rising oil and Iran-related uncertainty, will keep pressure on technology stocks. The community is split between buying the dip and expecting another leg lower.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

Will Generic Drug Tariffs Impact Pharma ETFs?

New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.

Why Did CANF Stock Soar 25% Today?

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Invesco Exchange-Traded Fund Trust - Invesco Pharmaceuticals ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Can-Fite BioPharma Ltd.

Exchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF

Invesco Dynamic Pharmaceuticals ETF

SPDR Pharmaceuticals ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

PJP Invesco Dynamic Pharmaceuticals ETF

Fundamentals

Latest PJP News